This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one’s immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out.AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA.This Plain Language Summary of Publication looks at ritlecitinib treatment for adults and adolescents with alopecia areata. This article from Immunotherapy is a summary of a study called ALLEGRO which looked at the effectiveness and safety of a medication called ritlecitinib for the treatment of alopecia areata (AA). AA is an autoimmune disease which attacks hair follicles causing the hair to fall out.

You can read the full article here.

The original article on which this summary is based was published in The Lancet. It is called ‘Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial’.

You can read the original article here.